患者总体评估对类风湿关节炎缓解达标的影响:基于METEOR数据库的多国研究
该横断面多国研究纳入27768例类风湿关节炎患者,分析患者总体评估(PtGA)对ACR/EULAR布尔缓解定义的影响。排除PtGA的3变量定义使缓解率从5.8%升至15.8%,仅因PtGA未达标者(PtGA近缓解)比例国家间差异大(印度1.7%至葡萄牙17.9%),疼痛和功能是PtGA主要相关因素。
要点
- 排除PtGA的3变量布尔定义使缓解率从5.8%升至15.8%。
- 仅因PtGA未达标的近缓解率国家间差异大,印度1.7%至葡萄牙17.9%。
- 疼痛和功能是PtGA主要相关因素,炎症变量贡献较小(R²=0.57)。
核心结论
- PtGA总体与关节炎症中度相关,但在低疾病活动度时仅弱相关。
- 相当比例生物制剂缓解患者仍有高PtGA,面临过度免疫抑制治疗风险。
研究设计与样本
- 横断面研究,使用METEOR国际数据库数据,纳入27768例类风湿关节炎患者。
- 计算仅因PtGA未达ACR/EULAR布尔缓解(4变量缓解)的患者比例(PtGA近缓解),并在代表性国家间比较。
- 采用多变量线性回归模型分析PtGA的主要决定因素,分为炎症影响因素(28个压痛关节数、28个肿胀关节数、C反应蛋白)和疾病影响因素(疼痛和功能)。
主要发现
- 排除PtGA的3变量布尔定义使缓解率从5.8%升至15.8%。
- PtGA近缓解率国家间差异大,从印度1.7%至葡萄牙17.9%。
- PtGA近缓解组中三分之一患者PtGA>4/10。
- 疼痛和功能是PtGA主要相关因素,炎症相关变量对模型贡献较小(R²=0.57)。
关键数值与推荐
- ACR/EULAR布尔缓解定义为4变量缓解,排除PtGA后为3变量缓解。
- PtGA近缓解定义为仅因PtGA未达布尔缓解。
- 代表性国家指数据库中有超过3000例患者的国家。
临床怎么用
- 临床评估RA缓解时应关注PtGA,避免仅因PtGA未达标而过度免疫抑制治疗。
- 对PtGA近缓解患者,需综合评估疼痛和功能等疾病影响因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is an ongoing debate about excluding patient's global assessment (PtGA) from composite and Boolean-based definitions of rheumatoid arthritis (RA) remission. This study aimed at determining the influence of PtGA on RA disease states, exploring differences across countries, and understanding the association between PtGA, measures of disease impact (symptoms), and markers of disease activity (inflammation). METHODS: Cross-sectional data from the Measurement of Efficacy of Treatment in the Era of Outcome in Rheumatology international database were used. We calculated the proportion of patients failing American College of Rheumatology/European League Against Rheumatism Boolean-based remission (4-variable remission) solely due to PtGA (PtGA-near-remission) in the overall sample and in the most representative countries (i.e., those with >3,000 patients in the database). Multivariable linear regression models were used to identify the main determinants of PtGA, grouped in predominantly inflammatory impact factors (28 tender joint counts, 28 swollen joint counts, and C-reactive protein level) and disease impact factors (pain and function). RESULTS: This study included 27,768 patients. Excluding PtGA from the Boolean-based definition (3-variable remission) increased the remission rate from 5.8% to 15.8%. The rate of PtGA-near-remission varied considerably between countries, from 1.7% in India to 17.9% in Portugal. One-third of the patients in PtGA-near-remission group scored PtGA >4 of 10. Pain and function were the main correlates of PtGA, with inflammation-related variables contributing less to the model (R2 = 0.57). CONCLUSION: PtGA is moderately related to joint inflammation overall, but only weakly so in low levels of disease activity. A considerable proportion of patients otherwise in biologic remission still perceive high PtGA, putting them at risk of excessive immunosuppressive treatment.
引用
- Ferreira RJO, Carvalho PD, Ndosi M, et al. Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. Arthritis Care Res (Hoboken). 2019. PMID: 30821895. doi:10.1002/acr.23866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。